Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF)
- 1 July 2016
- journal article
- research article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 22 (7) , 539-544
Abstract
No abstract availableKeywords
Funding Information
- Swedish Heart-Lung Foundation (20140376)
This publication has 37 references indexed in Scilit:
- Spectrum of Epidemiological and Clinical Findings in Patients with Heart Failure with Preserved Ejection Fraction Stratified by Study Design: A Systematic ReviewEuropean Journal of Heart Failure, 2015
- Spironolactone for Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2014
- Heart failure with preserved ejection fraction: a clinical dilemmaEuropean Heart Journal, 2014
- Effects of Carvedilol on Heart Failure with Preserved Ejection Fraction: the Japanese Diastolic Heart Failure Study (J-DHF)European Journal of Heart Failure, 2013
- Irbesartan in Patients with Heart Failure and Preserved Ejection FractionNew England Journal of Medicine, 2008
- Heart failure therapy in the elderly: Where are we? What are we doing?International Journal of Cardiology, 2008
- Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based studyEuropean Heart Journal, 2007
- The perindopril in elderly people with chronic heart failure (PEP-CHF) studyEuropean Heart Journal, 2006
- Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based StudyNew England Journal of Medicine, 2006
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003